Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    ACP Recommends HIV Screening for All Patients, Regardless of Risk Factors - (DGNews)
    FDA Grants Full Approval of Maraviroc for Treatment-Experienced Patients With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 11/24/2008 - (DGNews)
    Early Antiretroviral Therapy and Mortality among HIV-Infected Infants - (N Engl J Med)
    Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - AIDS and HIV

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Soft Tissue Non-Hodgkin Lymphoma of Shoulder in a HIV Patient: A Report of a Case and Review of the Literature
      HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
      Primary Kaposi Sarcoma of the Subcutaneous Tissue
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      HIV-2 Diagnosis and Quantification in High-Risk Patients

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Antiretrovirals Appear Safe During Pregnancy: Presented at ACOG

      By Maggie Schwarz

      WASHINGTON, D.C. -- May 11, 2006 -- The safety of 28 antiretrovirals in HIV-positive pregnant women has been assessed in nearly 6000 pregnancies and only 1 agent was identified as being associated with a risk for birth defects, according to research presented here at the 54th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG).

      Brenda Ross, MD, assistant professor of maternal-fetal medicine, Johns Hopkins Medical Center, Baltimore, Maryland, presented the research on a population of 5829 pregnancies registered in the multinational, voluntary, collaborative Antiretroviral Pregnancy Registry, which monitors pregnancy exposures for signals of a possible increase in the incidence of birth defects.

      Most women in the registry are taking 3 medications but they can be on just 1 to be enrolled. The median age of women whose pregnancies are registered is 28 years (range 13-48 years). Ninety percent of reports originated in the United States. Also included in the registry are the United Kingdom, France, Germany, Australia, Brazil, and South Africa, among others.

      Of 5829 evaluable pregnancies to date, 5560 resulted in live births. Of these, 2.6% involved at least 1 birth defect. The rate of birth defects reported in the general population is 3.1%, according to the Centers for Disease Control and Prevention.

      Among first-trimester antiretroviral exposures, 2.9% of 2117 of pregnancies involved a birth defect.

      The only agent to present a problem was efavirenz (Sustiva' Stocrin). Teratogenicity risk for this agent was noted and a warning included in the labeling several years ago.

      Dr. Ross concluded, "Antiretrovirals are generally safe. It's important to register patients so we can continue to determine teratogenic potential. All patients are enrolled anonymously."


      [Presentation title: The Antiretroviral Pregnancy Registry: 15 Years of Progress and 15 Years of Data. Abstract p. 41S]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send